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cis-Urocanic Acid Stimulates Primary Human
Keratinocytes Independently of Serotonin or
Platelet-Activating Factor Receptors
Kazuyo Kaneko1, Jeffrey B. Travers2, Mary S. Matsui3, Antony R. Young1, Mary Norval4 and Susan L. Walker1
Urocanic acid (UCA) is a major epidermal chromophore that undergoes trans to cis isomerization after
ultraviolet radiation (UVR). cis-UCA suppresses cell-mediated immunity. Recent studies suggest that cis-UCA
binds to serotonin (5-hydroxytryptamine) 2A (5-HT2A) receptor and that antagonists of 5-HT2A and the platelet-
activating factor (PAF) receptor can block cis-UCA-induced immune suppression in mice. Here, we examined
the involvement of 5-HT2A and PAF receptors in the ability of cis-UCA to stimulate immunomodulatory mediator
production in primary human keratinocytes. Using real-time reverse transcription-PCR (RT-PCR), PAF but not
5-HT2A receptor mRNA was constitutively expressed in primary human keratinocytes. Treatment with cis-UCA
increased prostaglandin E2 (PGE2), tumor necrosis factor-a (TNF-a), and IL-6 secretion, whereas 5-HT only
stimulated IL-6 production. Pretreatment with a 5-HT receptor antagonist partially inhibited IL-6 increase by
5-HT, but did not inhibit mediator production by cis-UCA. Similarly, a PAF receptor antagonist did not inhibit
cis-UCA-induced increase in PGE2. Intracellular calcium mobilization studies using a human epithelial cell line
stably transfected with PAF receptor also showed little evidence that cis-UCA stimulated PAF receptor and it did
not bind to this receptor. Thus, cis-UCA stimulates mediator production by a pathway that is independent of
these receptors in human keratinocytes, and these cells may not be the major target for cis-UCA-induced
immune suppression.
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INTRODUCTION
Exposure to solar ultravoilet radiation (UVR) (B295 to
400 nm) suppresses cell-mediated immunity in healthy hu-
mans (Kelly et al., 2000). The data from animal models have
shown that UVR-induced immune suppression plays an
important role in photocarcinogenesis and immunity to
pathogens allowing tumor cells/pathogens to evade immune
surveillance and persist in the host (Fisher and Kripke, 1977;
Termorshuizen et al., 2002). A similar role is suspected in
humans, yet the role of UVR-induced immune suppression in
humans is not fully understood (Termorshuizen et al., 2002;
Norval, 2006).
The molecular mechanisms underlying UVR-induced
immune suppression are complex and unclear, but absorption
of UV photons by epidermal chromophores (photoreceptors)
is required to initiate the biological response. Urocanic acid
(UCA), a deamination product of histidine, is a major
epidermal chromophore and present as trans-isomer in the
stratum corneum. Upon absorption of UVR, trans-UCA
undergoes a photoisomerization to its cis-isomer. There is
considerable evidence that topical or systemic application of
cis-UCA but not trans-UCA can suppress cell-mediated
immunity and mimic many of the immunomodulatory effects
of UVR in mice (Gibbs et al., 2008).
It has long been hypothesized that the effects of cis-UCA
are mediated through a membrane receptor. Although a
specific keratinocyte receptor for cis-UCA has not yet been
identified, Walterscheid et al. (2006) have recently reported
that cis-UCA may act through the serotonin (5-hydroxytryp-
tamine) 2A (5-HT2A) receptor because of structural
similarities between cis-UCA and 5-HT. They showed that
cis-UCA competitively binds to the 5-HT2A receptor and
activates cells through the 5-HT2A receptor by measuring
intracellular calcium mobilization in a human 5-HT2A
receptor overexpressing in vitro model system. In addition,
a 5-HT2A receptor antagonist inhibited cis-UCA-induced
suppression of the delayed-type hypersensitivity response
in mice.
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Besides cis-UCA, the production of the lipid mediator of
inflammation, platelet-activating factor (PAF), is an early
event in UVR-induced immunosuppression. PAF and its
analogs are secreted by epidermal cells in response to the
oxidative stress induced by UVR (Calignano et al., 1988;
Barber et al., 1998) and exert effects through the PAF
receptor expressed in various cell types, including mono-
cytes, mast cells, and keratinocytes (Simon et al., 1994;
Travers et al., 1995; Nilsson et al., 2000). Studies in
mice have shown that PAF receptor antagonists inhibit
UVR-induced immune suppression. A cyclooxygenase-2
(COX-2) inhibitor and an IL-10-neutralizing antibody block
the PAF-induced reduction in delayed-type hypersensitivity
and contact hypersensitivity responses, suggesting that PAF
initiates a cytokine cascade through prostaglandin E2 (PGE2)
release that leads to immune suppression (Walterscheid
et al., 2002; Zhang et al., 2008). Interestingly, Walterscheid
et al. have shown that a PAF receptor antagonist as well as a
5-HT2A receptor antagonist inhibit cis-UCA-induced suppres-
sion of the delayed-type hypersensitivity response in mice. In
addition, either antagonist can inhibit photocarcinogenesis in
mice (Sreevidya et al., 2008).
The mechanism of action of cis-UCA is still poorly
understood. As the photoisomerization to cis-UCA
takes place in the epidermis, keratinocytes may be a
potential target for cis-UCA. We have shown earlier that,
in primary human keratinocytes, cis-UCA upregulates
UVR-inducible genes including COX-2, resulting in increased
production of immunomodulatory mediators such as
PGE2, tumor necrosis factor-a (TNF-a), and IL-6 (Kaneko
et al., 2008). The release of PGE2 from keratinocytes
has been suggested as initiating IL-4 and then IL-10
production in serum, thus leading to systemic immune
suppression (Shreedhar et al., 1998). IL-4 is unlikely to be
secreted by keratinocytes (Shreedhar et al., 1998), and
it is debatable whether human keratinocytes produce IL-10
after UVR exposure (Jackson et al., 1996; Teunissen et al.,
1997). We were also unable to detect either IL-4 or IL-10
protein in keratinocytes after UCA or UVR treatment.
In addition, the immunosuppressive effects of cis-UCA
may be partially mediated by TNF-a, as anti-TNF-a-treated
mice show a reduced cis-UCA-induced suppression of the
contact hypersensitivity response (Kurimoto and Streilein,
1992).
The aim of this study was to determine whether the 5-HT2A
and PAF receptors are involved in the ability of cis-UCA to
stimulate the production of PGE2, TNF-a, and IL-6 in primary
human keratinocytes.
RESULTS
Keratinocytes express PAF but not 5-HT2A receptor mRNA
First, we assessed the expression of 5-HT2A and PAF receptor
mRNAs in primary human keratinocytes derived from three
donors (Figure 1). Unexpectedly, 5-HT2A receptor mRNA was
not detected, but PAF receptor mRNA was constitutively
expressed in keratinocytes. We analyzed further eight
primary human keratinocyte lines for 5-HT2A receptor
mRNA, but it was not detected (data not shown). In contrast,
both 5-HT2A and PAF receptor mRNAs were detected in
primary human fibroblasts (Figure 1).
cis-UCA induces PGE2 and cytokine release that are not
inhibited by the 5-HT receptor antagonist, Metergoline
5-HT receptors are classified into seven distinct families
including at least 14 subtypes (Barnes and Sharp, 1999). To
examine the involvement of any 5-HT receptors in cis-UCA-
mediated production of immunomodulatory mediators,
primary human keratinocytes were treated with cis-UCA
(70 or 700mM) or 5-HT (0.1 or 1mM) for 24 hours, and their
effects on PGE2 and cytokine production were compared. As
shown in Figure 2, treatment with 700mM cis-UCA increased
PGE2, IL-6, and TNF-a secretion into the cell culture
supernatant after 24 hours. In contrast, 1mM 5-HT stimulated
only IL-6 production and had no effect on PGE2 and TNF-a
secretion. Similar trends were observed at a lower concen-
tration (data not shown). In addition, the pretreatment with
Metergoline, an antagonist of 5-HT1, 5-HT2, and 5-HT7
receptors (Martin and Sanders-Bush, 1982; Bard et al., 1993;
Audinot et al., 1997), had no inhibitory effect on cis-UCA-
mediated PGE2 or cytokine production, although the IL-6
increase by 5-HT was partially but significantly inhibited
(Figure 2). The results suggest that cis-UCA induces mediator
production independently of 5-HT receptor signaling path-
ways.
cis-UCA is unlikely to stimulate and does not bind to the PAF
receptor in the PAF-receptor-transfected human epithelial cells
Having confirmed that primary human keratinocytes
constitutively express the PAF receptor, we firstly carried
out calcium mobilization studies using the KB PAF receptor
model system to evaluate the ability of cis-UCA to stimulate
the PAF receptor. The human epithelial KB cell line
does not express functional PAF receptor (Pei et al., 1998).
The results are given in Figure 3a. PAF caused a transient
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Figure 1. mRNA expression of 5HT2A and PAF receptors in primary human
keratinocytes and fibroblasts. 5HT2A (open column) and PAF (shaded
column) receptor mRNA expressions were quantified using real-time RT-PCR
(TaqMan). The results are expressed as mean±SD of three donors. ND, not
detected.
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intracellular Ca2þ flux in PAF-receptor-transfected KBP
cells, but had no effect on vector-only-transfected PAF-
receptor-negative KBM cells. Treatment with cis-UCA also
resulted in a weak and delayed Ca2þ flux in KBP cells,
which was considered insignificant, and had no effect in
KBM cells. Treatment with trans-UCA did not alter
intracellular Ca2þ levels in either KBP or KBM cells.
In addition, no calcium flux was observed in either KBP or
KBM cells when the cells were treated with 5-HT (data not
shown).
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Figure 2. 5HT receptor antagonist has no inhibitory effect on cis-urocanic acid-induced mediator production in primary human keratinocytes. Keratinocytes
were pretreated with 10 mM Metergoline (shaded column) or ethanol vehicle (open column) for 1 hour before treatment with PBS, cis-UCA (700 mM), or 5HT
(1mM) for 24 hours. Cell culture supernatants were collected and analyzed for (a) PGE2, (b) TNF-a, and (c) IL-6 by ELISA. The results are expressed as mean±SD
(n¼3) of one representative experiment of three. *Po0.05, **Po0.01, and ***Po0.001 compared with PBS control.
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Figure 3. cis-Urocanic acid is unlikely to stimulate the PAF receptor and has minimal effects on PAF-receptor-mediated PGE2 production in the KB PAF
receptor model system. (a) Calcium mobilization responses of PAF-receptor-positive KBP and PAF-receptor-negative KBM cells in response to cis-UCA and
trans-UCA (140 mM) and PAF (100 nM). Fluorescence intensity of Ca2þ -sensitive dye Fura-2 was measured over time with a spectrophotofluorometer. The data
represent one of three independent experiments. (b) Displacement of radioligand binding (10 nM [3H]WEB2086) from the PAF receptor by cis-UCA (50–500mM)
and trans-UCA (500mM), and by PAF (1 mM) in KBP cells. (c) PGE2 release from KBP (shaded column) and KBM (open column) cells treated with PBS, cis-UCA (70
and 700 mM) or trans-UCA (700mM), or with PAF (100 nM) for 24 hours. PGE2 concentrations in cell culture supernatants were assessed by ELISA. Results are
expressed as mean±SD (n¼ 3) of one representative experiment of three. ***Po0.001 compared with PBS control. NS, not significant.
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To determine whether cis-UCA might bind to the PAF
receptor, KBP cells were treated with [3H]WEB2086, a
radiolabeled PAF receptor antagonist, with or without cis-
UCA or trans-UCA, or PAF at 4 1C to quantify the displace-
ment of [3H]WEB2086 from the PAF receptor. As shown in
Figure 3b, the addition of 1 mM PAF resulted in a significant
decrease in [3H]WEB2086 binding to the PAF receptor. In
contrast, neither cis-UCA nor trans-UCA up to 500mM could
compete with [3H]WEB2086 for binding to the PAF receptor,
suggesting that cis-UCA can stimulate the PAF receptor
without direct binding to it.
cis-UCA has minimal effects on PAF-receptor-mediated PGE2
production
Both cis-UCA and PAF induce COX-2 and increase PGE2
release (Pei et al., 1998; Kaneko et al., 2008). We further
examined whether cis-UCA enhances PGE2 production
through the PAF receptor. As shown in Figure 3c, PAF
significantly enhanced PGE2 secretion into the cell culture
supernatant only in PAF-receptor-positive KBP cells but not in
KBM cells. cis-UCA tended to increase PGE2 release in both
KBP and KBM cells, although the increase was significant
only at 700mM in the KBP cells, and no significant difference
was seen in the increase between KBM and KBP cells. trans-
UCA had no effect on PGE2 release in either cells.
To confirm the results obtained in the KB PAF receptor
model system, primary human keratinocytes were pretreated
with 10 mM of ABT-491, a PAF receptor antagonist (Albert
et al., 1997), for 1 hour before treatment with cis-UCA or PAF
for 24 hours. As shown in Figure 4, the pretreatment with
ABT-491 almost completely blocked the PAF-induced
increase in PGE2 release, but had no inhibitory effect on
the PGE2 increase by cis-UCA. Taken together, the results
suggest that the involvement of the PAF receptor in cis-UCA-
induced PGE2 production is minimal.
DISCUSSION
The release of immunomodulatory mediators is an important
event in the initiation of UVR-induced immune suppression.
In this study, we tested the hypothesis that cis-UCA increases
PGE2 and cytokine production through 5-HT2A and/or PAF
receptor in primary human keratinocytes. Our results suggest
that cis-UCA stimulates the production of these mediators by
a pathway that is independent of these receptors in primary
human keratinocytes.
Slominski et al. (2003) have reported that primary human
epidermal keratinocytes and dermal fibroblasts express
5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT7 receptor
mRNAs. However, we did not detect 5-HT2A receptor mRNA
in 11 primary human keratinocyte lines (Figure 1), neither
could we detect the mRNA expression of 5-HT2A receptor in
the same cell lines 6 hours after exposure to a physiologically
relevant dose (12 J cm2) of solar-simulated UVR (data not
shown). This was the case despite using a quantitative
TaqMan real-time reverse transcriptase-PCR (RT-PCR) with a
specific TaqMan probe, which is more sensitive than the
earlier authors’ qualitative gel-based RT-PCR method. The
TaqMan probe and primers we used were designed across an
exon–exon boundary that ensures that the signal is generated
only from RNA, whereas the primers used by Slominski et al.
were designed within single exon that may have amplified
genomic DNA.
There are no reports on the role of 5-HT receptor signaling
on mediator production in keratinocytes, but it has been
shown that 5-HT modulates cytokine and PGE2 release
through 5-HT1, 5-HT2, 5-HT3, 5-HT4, and/or 5-HT7 receptors
in other cell types, including human airway epithelial cells,
monocytes, and dendritic cells (Cloez-Tayarani et al., 2003;
Idzko et al., 2004; Durk et al., 2005; Bayer et al., 2007). Our
results indicated that 5-HT stimulated IL-6 release mediated
through 5-HT1, 5-HT2, and/or 5-HT7 receptors, but had no
effect on PGE2 or TNF-a release in primary human
keratinocytes (Figure 2). cis-UCA also increased IL-6 release,
an effect not inhibited by a 5-HT receptor antagonist,
indicating that 5-HT and cis-UCA stimulate IL-6 release by
different mechanisms in human keratinocytes. However,
Reeve et al. (2009) have reported that suppression of the
contact hypersensitivity response by cis-UCA was not altered
in the IL-6/ mice, suggesting that IL-6 is unlikely to be
involved in cis-UCA-induced immune suppression. Unlike
5-HT, cis-UCA enhanced PGE2 and TNF-a release, and
neither of these was blocked by a 5-HT receptor antagonist.
Consistent with our results, Woodward et al. (2006) also
suggest that cis-UCA does not regulate immunomodulatory
mediator production through the 5-HT2A receptor, although
their test system involved human peripheral blood mono-
nuclear cells rather than keratinocytes. Human peripheral
blood mononuclear cells have been reported to express
5-HT1A, 5-HT1B, 5-HT1E, 5-HT2A, 5-HT3, 5-HT4, and 5-HT6
receptors (Yang et al., 2006). Woodward et al. showed that
cis-UCA increased PGE2 release in a dose-dependent
manner, but a supraphysiological concentration of 5-HT
was required to induce the same level of PGE2. Similarly,
both cis-UCA and 5-HT suppressed lipopolysaccharide-
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Figure 4. PAF receptor antagonist does not inhibit PGE2 increase by cis-
urocanic acid in primary human keratinocytes. Keratinocytes were pretreated
with 10 mM ABT-491 (shaded column) or with water vehicle (open column) for
1 hour before treatment with PBS, cis-UCA (70 or 700mM), or PAF (1 mM) for
24 hours. Cell culture supernatants were collected and analyzed for PGE2 by
ELISA. Results are expressed as mean±SD (n¼3) of one representative
experiment of three. *Po0.05, **Po0.01, and ***Po0.001 compared with
PBS control.
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induced TNF-a production. However, indomethacin,
a COX inhibitor, completely abrogated the suppression by
cis-UCA, whereas significant suppression by 5-HT remained
in the presence of indomethacin. Although the studies relied
on the in vitro response to cis-UCA and thus may not
necessarily reflect in vivo situations, there is a possibility
that other receptor signaling pathways are involved in
the production of immunomodulatory mediators by
cis-UCA in humans.
Expression of the PAF receptor in keratinocytes has been
reported (Travers et al., 1995) and we also detected the PAF
receptor. Using the KB PAF receptor model, we did not
obtain convincing evidence that cis-UCA stimulated the PAF
receptor (Figure 3). The delay in the onset of the calcium
response to cis-UCA suggests that cis-UCA could induce its
effects on intracellular Ca2þ levels in KBP cells by the
generation of endogenous PAF agonists as has been shown
for staphylococcal alpha-toxin (Travers et al., 2003). As
mentioned in the Introduction section, PAF is synthesized in
response to stress induced by various stimuli including UVR
(Calignano et al., 1988; Barber et al., 1998; Alappatt et al.,
2000). Our earlier study showed that cis-UCA causes
oxidative stress (Kaneko et al., 2008), and also Steenvoorden
and Beijersbergen van (1999) reported that topical treatment
with antioxidants inhibited cis-UCA-induced local immune
suppression in mice, suggesting that cis-UCA may stimulate
the PAF receptor as a result of a stress response. However, our
results showed that cis-UCA had only minimal effects on
PGE2 production through the PAF receptor. Neither over-
expression of the PAF receptor nor a PAF receptor antagonist
affected the increase in PGE2 release induced by cis-UCA
(Figures 3c and 4). It is concluded that PAF receptor signaling
is not the main pathway by which cis-UCA induces PGE2
synthesis in human keratinocytes.
The data published by Walterscheid et al. (2006) showed
that cis-UCA activates the 5-HT2A receptor in an in vitro
model system, but did not provide evidence to conclude that
cis-UCA exerts its effects through direct binding to the
5-HT2A receptor in vivo. They reported that an antibody
against 5-HT blocked suppression of the delayed-type
hypersensitivity response by cis-UCA in mice. This implies
that the 5-HT antibody captures cis-UCA and blocks the
binding of cis-UCA to specific receptors. The cell type or
types involved and their location were not identified.
Matsumura et al. (2006) have reported that inhibition of both
PAF and 5-HT2A receptor binding is necessary to block UVR-
induced immune suppression, and Sreevidya et al. (2008)
found that PAF and 5-HT2A receptor antagonists act in a
synergistic manner to prevent UVR-induced skin tumors.
These results indicate that 5-HT2A and PAF receptors are
closely related to each other in UVR-induced immune sup-
pression. There is considerable evidence that PAF induces
5-HT release from platelets, which are a major source of skin
5-HT (Kravis and Henson, 1975; Chesney et al., 1982; Bailey
et al., 2000; Nordlind et al., 2008). For the activation of
platelets, only picomolar levels of PAF are required. Although
our data did not confirm that cis-UCA enhances mediator
production through the PAF receptor in keratinocytes, cis-UCA
stimulation of the PAF receptor may be strong enough to
induce release of 5-HT from platelets, which then binds
to the 5-HT2A receptor possibly in mast cells and T cells,
resulting in immune suppression. Whether cis-UCA stimu-
lates 5-HT release remains to be seen. Walterscheid et al.
(2006) speculate that cis-UCA may bind to mast cells, thus
stimulating them to release PAF. However, studies in rat
and mouse peritoneal cells have shown that PAF is released
from macrophages, not from mast cells, and that PAF
production is unrelated to 5-HT release by activation of mast
cells (Mencia-Huerta and Benveniste, 1979; Pellon et al.,
1993). Thus, PAF release through 5-HT receptor is less likely
to happen.
Keratinocytes are a major source of cytokines in the skin,
and an important candidate for the site of action of cis-UCA.
Our findings suggest that there is a 5-HT2A receptor-
independent pathway for cis-UCA in human keratinocytes.
Further study is required to elucidate its identity but
activation of epidermal growth factor receptor may be
involved, as it is a well-established mechanism by which
UVR-induced reactive oxygen species lead to COX-2
expression and subsequent PGE2 production (Rundhaug and
Fischer, 2008). However, Zhang et al. (2008) report that, in
mice, immunomodulatory mediators from bone marrow-
derived dendritic cells and monocytes play a more important
role in UVR-induced immune suppression than those from
keratinocytes. It is possible that keratinocytes may not be the
primary target for cis-UCA-induced immune suppression, and
the role of 5-HT2A and PAF receptors in other cell types in the
skin remains to be determined.
MATERIALS AND METHODS
Cells
Primary cultures of epidermal keratinocytes were prepared from
biopsies taken from the unexposed buttock skin of healthy Caucasian
volunteers (for receptor mRNA expression) or from the face or from
the abdominal skin of healthy Caucasian donors who had undergone
cosmetic surgery (for cytokine and PGE2 release) as described earlier
(Kaneko et al., 2008). There was no difference in the effects of cis-
UCA between the keratinocytes from the different sites. Keratino-
cytes were grown in serum-free keratinocyte medium supplemented
with 50 mgml1 pituitary extract, 2.5 ngml1 epidermal growth
factor, 100Uml1 penicillin, and 100 mgml1 streptomycin (Invitro-
gen, Paisley, UK) and were used in experiments at the third passage.
Primary cultures of dermal fibroblasts were prepared from biopsies
taken from the unexposed buttock skin of healthy Caucasian
volunteers. Briefly, the dermis separated from epidermal sheets
was cut into pieces and placed into six-well plates to grow
fibroblasts in DMEM supplemented with 10% fetal bovine serum,
2mM L-glutamine, 100Uml1 penicillin, and 100 mgml1 strepto-
mycin (Invitrogen). The procedure was approved by St Thomas’
Hospital Ethics Committee, adhering to the Declaration of Helsinki
Principles, and the donors gave written informed consent. Human
epithelial KB cell lines stably transfected with the human PAF
receptor (designated as KBP cells) or with control MSCV2.1 retro-
virus (designated as KBM cells), prepared as described earlier (Pei
et al., 1998), were grown in DMEM supplemented with 10% fetal
bovine serum, 2mM L-glutamine, 50Uml1 penicillin, 50 mgml1
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streptomycin, 1% minimum essential medium non-essential amino
acids, and 1%minimum essential medium vitamins solution (Invitrogen).
All cells were maintained at 37 1C in 5% CO2, and the medium was
changed every 2–3 days. For all experiments, cells were fed 24hours
before treatment and allowed to grow to 80% confluency.
Reagents
All chemicals were obtained from Sigma-Aldrich Company Ltd.
(Dorset, UK), unless otherwise indicated. cis-UCA was prepared
from trans-UCA as described earlier and was 499% pure as
determined by HPLC (Norval et al., 1989). UCA isomers and 5-HT
were dissolved in phosphate-buffered saline (PBS) and PBS served as
a baseline control. PAF and Metergoline were dissolved in ethanol
and ABT-491 was dissolved in deionized water.
TaqMan real-time RT-PCR
Total RNA was extracted from primary human keratinocytes and
fibroblasts using RNA-Bee (Tel-Test, Friendswood, TX), and cDNA
was generated from total RNA of each sample using TaqMan Reverse
Transcription Reagents (Applied Biosystems, Foster City, CA)
following the manufacturer’s instructions. The expression level of
mRNA was analyzed by TaqMan real-time RT-PCR on an ABI Prism
7700 Sequence Detection System (Applied Biosystems) with the
following TaqMan probes: 5-HT2A receptor, Hs00167241_m1 and
PAF receptor, Hs00265392_s1, as provided by the manufacturer.
Glyceraldehyde-3-phosphate dehydrogenase served as an endogen-
ous control gene.
Intracellular calcium mobilization
KB cells were loaded with Ca2þ -sensitive dye Fura-2 AM (Invitro-
gen) and treated with PAF (100 nM), or with trans-UCA or cis-UCA
(140mM). Intracellular Ca2þ flux was measured as described earlier
(Travers et al., 1995).
Radioligand binding assays
Displacement of 10 nM [3H]WEB2086 (New England Nuclear Corp,
Boston, MA) radioligand binding to the PAF receptor by PAF (1 mM),
or by trans-UCA or cis-UCA (50–500 mM) was analyzed as described
earlier (Pei et al., 1998).
Cytokines and PGE2 measurements
Supernatants were collected 24 hours after treatment with trans-UCA
or cis-UCA, with 5-HT, or with PAF by centrifugation. TNF-a, IL-6,
and PGE2 concentrations were measured using DuoSet ELISA
kits (R&D Systems Europe, Abingdon, UK) and a Parameter PGE2
Assay (R&D Systems Europe) according to the manufacturer’s
instructions.
Statistical analysis
Student’s unpaired t-test was carried out using SPSS 11.5 software
(SPSS Inc., Chicago, IL). Values of Po0.05 were considered significant.
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